{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:58:05Z","timestamp":1790740685600,"version":"4.1.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"\u00d6rebro County Council Research Committee"},{"DOI":"10.13039\/501100011597","name":"Conselleria de Sanitat Universal i Salut P\u00fablica","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100011597","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"crossref","award":["CDEI-06\/20-B"],"award-info":[{"award-number":["CDEI-06\/20-B"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003359","name":"Generalitat Valenciana","doi-asserted-by":"crossref","award":["PID2020\u2013120113RA-I00"],"award-info":[{"award-number":["PID2020\u2013120113RA-I00"]}],"id":[{"id":"10.13039\/501100003359","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Antimicrobial resistance (AMR) in Neisseria gonorrhoeae is a global threat and novel treatment alternatives are imperative. Herein, susceptibility to the novel antimicrobial zoliflodacin, currently in a global Phase 3 randomized controlled clinical trial for gonorrhoea treatment, was investigated by screening for zoliflodacin GyrB target mutations in publicly available gonococcal genomes and, where feasible, determination of the associated zoliflodacin MIC.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The European Nucleotide Archive was queried using the search term \u2018Taxon: 485\u2019. DNA sequences from 27\u200a151 gonococcal isolates were analysed and gyrB, gyrA, parC and parE alleles characterized.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>GyrB amino acid alterations were rare (97.0% of isolates had a wild-type GyrB sequence). GyrB V470L (2.7% of isolates) was the most prevalent alteration, followed by S467N (0.12%), N. meningitidis GyrB (0.092%), V470I (0.059%), Q468R\/P (0.015%), A466T (0.0074%), L425I\u200a+\u200aL465I (0.0037%), L465I (0.0037%), G482S (0.0037%) and D429V (0.0037%). Only one isolate (0.0037%) carried a substitution in a resistance-associated GyrB codon (D429V), resulting in a zoliflodacin MIC of 8\u2005mg\/L. None of the other detected gyrB, gyrA, parC or parE mutations caused a zoliflodacin MIC outside the wild-type MIC distribution.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The zoliflodacin target GyrB was highly conserved among 27\u200a151 global gonococcal isolates cultured in 1928\u20132021. The single zoliflodacin-resistant clinical isolate (0.0037%) was cultured from a male patient in Japan in 2000. Evidently, this strain has not clonally expanded nor has the gyrB zoliflodacin-resistance mutation disseminated through horizontal gene transfer to other strains. Phenotypic and genomic surveillance, including gyrB mutations, of zoliflodacin susceptibility are imperative.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac366","type":"journal-article","created":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T11:48:21Z","timestamp":1667044101000},"page":"150-154","source":"Crossref","is-referenced-by-count":36,"title":["GyrB <i>in silico<\/i> mining in 27\u200a151 global gonococcal genomes from 1928\u20132021 combined with zoliflodacin <i>in vitro<\/i> testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility"],"prefix":"10.1093","volume":"78","author":[{"given":"Daniel","family":"Golparian","sequence":"first","affiliation":[{"name":"Department of Laboratory Medicine, Microbiology, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, \u00d6rebro University , \u00d6rebro , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Jacobsson","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Microbiology, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, \u00d6rebro University , \u00d6rebro , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonor","family":"S\u00e1nchez-Bus\u00f3","sequence":"additional","affiliation":[{"name":"Genomics and Health Area, Foundation for the Promotion of Health and Biomedical Research in the Valencian Community (FISABIO-Public Health), Valencia, Spain and Consortium for Biomedical Research in Epidemiology and Public Health (CIBERESP) , Madrid , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luiza","family":"Bazzo","sequence":"additional","affiliation":[{"name":"Molecular Biology, Microbiology and Serology Laboratory, Federal University of Santa Catarina , Florian\u00f3polis , Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pham Thi","family":"Lan","sequence":"additional","affiliation":[{"name":"Hanoi Medical University, National Hospital of Dermatology and Venereology , Hanoi , Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Galarza","sequence":"additional","affiliation":[{"name":"National Reference Laboratory for STDs, National Institute of Infectious Diseases\u2014ANLIS \u2018Dr Carlos G. Malbr\u00e1n\u2019 , Buenos Aires , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ohnishi","sequence":"additional","affiliation":[{"name":"Department of Bacteriology I, National Institute of Infectious Diseases , Tokyo , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1710-2081","authenticated-orcid":false,"given":"Magnus","family":"Unemo","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Microbiology, Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, \u00d6rebro University , \u00d6rebro , Sweden"},{"name":"Institute for Global Health, University College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"2023010801141305700_dkac366-B1","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2666-5247(21)00171-3","article-title":"WHO Global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017\u20132018: a retrospective observational study","volume":"2","author":"Unemo","year":"2021","journal-title":"Lancet Microbe"},{"key":"2023010801141305700_dkac366-B2","doi-asserted-by":"crossref","first-page":"2200455","DOI":"10.2807\/1560-7917.ES.2022.27.24.2200455","article-title":"Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022","volume":"27","author":"Pleininger","year":"2022","journal-title":"Euro Surveill"},{"key":"2023010801141305700_dkac366-B3","doi-asserted-by":"crossref","first-page":"1900118","DOI":"10.2807\/1560-7917.ES.2019.24.8.1900118","article-title":"Genetic relatedness of ceftriaxone-resistant and high-level azithromycin resistant Neisseria gonorrhoeae cases, United Kingdom and Australia, February to April 2018","volume":"24","author":"Jennison","year":"2019","journal-title":"Euro Surveill"},{"key":"2023010801141305700_dkac366-B4","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","article-title":"Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates","volume":"6","author":"Bradford","year":"2020","journal-title":"ACS Infect Dis"},{"key":"2023010801141305700_dkac366-B5","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N Engl J Med"},{"key":"2023010801141305700_dkac366-B6","doi-asserted-by":"crossref","first-page":"e01221-18","DOI":"10.1128\/AAC.01221-18","article-title":"Microbiological analysis from a phase 2 randomized study in adults evaluating single oral doses of gepotidacin in the treatment of uncomplicated urogenital gonorrhea caused by Neisseria gonorrhoeae","volume":"62","author":"Scangarella-Oman","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801141305700_dkac366-B7","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1093\/jac\/dkab024","article-title":"High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018","volume":"76","author":"Unemo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023010801141305700_dkac366-B8","doi-asserted-by":"crossref","first-page":"e00863-20","DOI":"10.1128\/AAC.00863-20","article-title":"Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing, China, 2014 to 2018","volume":"65","author":"Le","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801141305700_dkac366-B9","doi-asserted-by":"crossref","first-page":"682135","DOI":"10.3389\/fphar.2021.682135","article-title":"Pharmacodynamic evaluation of dosing, bacterial kill, and resistance suppression for zoliflodacin against Neisseria gonorrhoeae in a dynamic hollow fiber infection model","volume":"12","author":"Jacobsson","year":"2021","journal-title":"Front Pharmacol"},{"key":"2023010801141305700_dkac366-B10","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1093\/jac\/dkab262","article-title":"Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance","volume":"76","author":"Adamson","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2023010801141305700_dkac366-B11","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1128\/AAC.04456-14","article-title":"Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in Neisseria gonorrhoeae","volume":"59","author":"Alm","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801141305700_dkac366-B12","doi-asserted-by":"crossref","first-page":"874176","DOI":"10.3389\/fphar.2022.874176","article-title":"Pharmacodynamic evaluation of zoliflodacin treatment of Neisseria gonorrhoeae strains with amino acid substitutions in the zoliflodacin target GyrB using a dynamic hollow fiber infection model","volume":"13","author":"Jacobsson","year":"2022","journal-title":"Front Pharmacol"},{"key":"2023010801141305700_dkac366-B13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1128\/AAC.35.4.622","article-title":"Characterization of a gyrB mutation responsible for low-level nalidixic acid resistance in Neisseria gonorrhoeae","volume":"35","author":"Stein","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801141305700_dkac366-B14","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13073-021-00858-2","article-title":"A community-driven resource for genomic epidemiology and antimicrobial resistance prediction of Neisseria gonorrhoeae at pathogenwatch","volume":"13","author":"S\u00e1nchez-Bus\u00f3","year":"2021","journal-title":"Genome Med"},{"key":"2023010801141305700_dkac366-B15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12864-020-6511-6","article-title":"Genomic evolution of Neisseria gonorrhoeae since the preantibiotic era (1928\u20132013): antimicrobial use\/misuse selects for resistance and drives evolution","volume":"21","author":"Golparian","year":"2020","journal-title":"BMC Genomics"},{"key":"2023010801141305700_dkac366-B16","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1093\/jac\/dkw288","article-title":"The novel 2016 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations: phenotypic, genetic and reference genome characterization","volume":"71","author":"Unemo","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2023010801141305700_dkac366-B17","first-page":"e000056","article-title":"SNP-sites: rapid efficient extraction of SNPs from multi-FASTA alignments","volume":"2","author":"Page","year":"2016","journal-title":"Microb Genom"},{"key":"2023010801141305700_dkac366-B18","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1128\/AAC.03090-14","article-title":"High in vitro activity of the novel spiropyrimidinetrione AZD0914, a DNA gyrase inhibitor, against multidrug-resistant Neisseria gonorrhoeae isolates suggests a new effective option for oral treatment of gonorrhea","volume":"58","author":"Jacobsson","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023010801141305700_dkac366-B19","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41564-019-0501-y","article-title":"The impact of antimicrobials on gonococcal evolution","volume":"4","author":"S\u00e1nchez-Bus\u00f3","year":"2019","journal-title":"Nat Microbiol"},{"key":"2023010801141305700_dkac366-B20","doi-asserted-by":"crossref","first-page":"793612","DOI":"10.3389\/fmicb.2022.793612","article-title":"Horizontal gene transfer of fluoroquinolone resistance-conferring genes from commensal Neisseria to Neisseria gonorrhoeae: a global phylogenetic analysis of 20,047 isolates","volume":"13","author":"Manoharan-Basil","year":"2022","journal-title":"Front Microbiol"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/1\/150\/48444468\/dkac366.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/78\/1\/150\/48444468\/dkac366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T01:14:35Z","timestamp":1673140475000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/78\/1\/150\/6779860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,10,29]]},"published-print":{"date-parts":[[2023,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac366","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,5]]},"published":{"date-parts":[[2022,10,29]]}}}